Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.67 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 5/20 | 0.45 |
| ▸ | F7 | P08709 | 1/20 | 0.45 |
| ▸ | F3 | P13726 | 1/20 | 0.45 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.45 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2714659 | 1.00 | HCAR2 (0.67) | HCAR2PARP1CYP11B2SIRT2SIRT1 | |
| SCHEMBL2841794 | 0.84 | SIRT2 (0.54) | HCAR2CYP11B2SIRT2SIRT1SIRT3 | |
| SCHEMBL30475710 | 0.80 | HCAR2 (0.58) | HCAR2PARP1CYP11B2SIRT2SIRT1 | |
| SCHEMBL29033011 | 0.80 | HCAR2 (0.58) | HCAR2PARP1CYP11B2SIRT2SIRT1 | |
| 5-Fluoronicotinic Acid SCHEMBL29951819 | 0.80 | HCAR2 (1.00) | HCAR2MKNK1MKNK2RAF1KDM4E | |
| 5-Fluoronicotinic Acid SCHEMBL430582 | 0.80 | HCAR2 (1.00) | HCAR2MKNK1MKNK2RAF1KDM4E | |
| SCHEMBL31242967 | 0.79 | CYP11B2 (0.55) | HCAR2CYP11B2MKNK1MKNK2MAP4K4 | |
| SCHEMBL27987797 | 0.79 | CYP11B2 (0.55) | HCAR2CYP11B2MKNK1MKNK2MAP4K4 | |
| SCHEMBL2584679 | 0.78 | HCAR2 (0.67) | HCAR2KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL2722765 | 0.78 | HCAR2 (0.67) | HCAR2CYP11B2MKNK1MKNK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | claimed |
| US-20230133600-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-05-04 | — | — | US | claimed |
| EP-4098258-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-12-07 | — | — | EP | claimed |
| US-12636275-B2 | Pharmaceutical use of ketoamide-based compound | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2026-05-26 | — | — | US | disclosed |
| US-12152017-B2 | Ketoamide compound and preparation method, pharmaceutical composition, and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2024-11-26 | — | — | US | disclosed |
| CN-117720533-A | MetTL3 inhibitor compound and pharmaceutical composition and application thereof | 北京华益健康药物研究中心 | 2024-03-19 | — | — | CN | disclosed |
| EP-4322954-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2024-02-21 | — | — | EP | disclosed |
| EP-4037670-A4 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | Tenaya Therapeutics, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230133600-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230123856-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | TENAYA THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4098258-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-12-07 | — | — | EP | disclosed |
| WO-2022221739-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-10-20 | — | — | WO | disclosed |
| EP-4037670-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | Tenaya Therapeutics, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| EP-4037670-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | Tenaya Therapeutics, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| US-20220112177-A1 | KETOAMIDE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | FUDAN UNIVERSITY (CN) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112177-A1 | KETOAMIDE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | ACE, REN, ACE2 | HCAR2 311/4885PARP1 2883/4885CYP11B2 281/4885 |
| US-20230133600-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | CTSL, CTSV, CTSS | HCAR2 275/4885PARP1 3961/4885CYP11B2 1338/4885 |
| US-12636275-B2 | Pharmaceutical use of ketoamide-based compound | CTSV, CTSL, CTSS | HCAR2 488/4885PARP1 2864/4885CYP11B2 1234/4885 |
| US-12152017-B2 | Ketoamide compound and preparation method, pharmaceutical composition, and use thereof | ACE, REN, ACE2 | HCAR2 311/4885PARP1 2883/4885CYP11B2 281/4885 |
| US-20230123856-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | SLC28A1, SLC5A1, SLC9A5 | HCAR2 2192/4885PARP1 4242/4885CYP11B2 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.